Skip to content

Study · Animal study (in vivo) · chick and rat · 2017

10 results

Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.

Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS

Journal of molecular medicine (Berlin, Germany)15 Nov 2016Cited by 87 (Europe PMC)

PMID27847966 (opens in a new tab)DOI10.1007/s00109-016-1488-y (opens in a new tab)PepBankPUB-27847966
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In the chick chorioallantoic membrane assay, BPC‑157 increased vessel density in vivo.

    In plain wordsIn chick embryos, BPC‑157 increased blood vessel density.

    Peptide
    BPC-157
    Outcome
    IncreaseVessel density in CAM assay
    Study

    chickn: not reported in source

    Chick chorioallantoic membrane assay
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    As demonstrated by the chick chorioallantoic membrane (CAM) assay
    1 context sentence
    Summary · context
    BPC 157 could increase the vessel density both in vivo and in vitro, respectively.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with hind limb ischemia, BPC‑157 accelerated the recovery of blood flow in ischemic muscle.

    In plain wordsIn rats with a blocked hind limb blood supply, BPC‑157 sped up blood flow recovery.

    Peptide
    BPC-157
    Outcome
    IncreaseBlood flow recovery in ischemic hind limb
    Study

    ratn: not reported in source

    Rat hind limb ischemia
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    BPC 157 could also accelerate the recovery of blood flow in the ischemic muscle of the rat hind limb as detected by laser Doppler scanning, indicating the promotion of angiogenesis.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with hind limb ischemia, histology confirmed an increased number of vessels with BPC‑157 treatment.

    In plain wordsIn rats with a blocked hind limb blood supply, BPC‑157 increased the number of blood vessels in the muscle.

    Peptide
    BPC-157
    Outcome
    IncreaseVessel number in ischemic hind limb muscle
    Study

    ratn: not reported in source

    Rat hind limb ischemia
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Histological analysis of the hind limb muscle confirmed the increased number of vessels and the enhanced vascular expression of vascular endothelial growth factor receptor 2 (VEGFR2) in rat with BPC 157 treatment.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats with hind limb ischemia, BPC‑157 treatment enhanced vascular expression of VEGFR2.

    In plain wordsIn rats with a blocked hind limb blood supply, BPC‑157 raised VEGFR2 levels in blood vessels.

    Peptide
    BPC-157
    Outcome
    IncreaseVascular VEGFR2 expression in ischemic hind limb muscle
    Study

    ratn: not reported in source

    Rat hind limb ischemia
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Histological analysis of the hind limb muscle confirmed the increased number of vessels and the enhanced vascular expression of vascular endothelial growth factor receptor 2 (VEGFR2) in rat with BPC 157 treatment.
  5. 05LabIn vitro (cells)Efficacy outcome

    In an endothelial tube formation assay, BPC‑157 increased vessel density in vitro.

    In plain wordsIn lab-grown blood vessel cells, BPC‑157 increased tube formation.

    Peptide
    BPC-157
    Outcome
    IncreaseEndothelial tube formation
    Study

    n: not reported in source

    Endothelial tube formation assay
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    As demonstrated by the chick chorioallantoic membrane (CAM) assay and endothelial tube formation assay, BPC 157 could increase the vessel density both in vivo and in vitro, respectively.
  6. 06LabIn vitro (cells)Mechanism

    In human vascular endothelial cells, BPC‑157 increased VEGFR2 mRNA expression.

    In plain wordsIn human blood vessel cells in the lab, BPC‑157 increased VEGFR2 mRNA.

    Peptide
    BPC-157
    Outcome
    IncreaseVEGFR2 mRNA expression
    Study

    humann: not reported in source

    Human vascular endothelial cells
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro study using human vascular endothelial cells further confirmed the increased mRNA and protein expressions of VEGFR2 but not VEGF-A by BPC 157.
  7. 07LabIn vitro (cells)Mechanism

    In human vascular endothelial cells, BPC‑157 increased VEGFR2 protein expression.

    In plain wordsIn human blood vessel cells in the lab, BPC‑157 increased VEGFR2 protein.

    Peptide
    BPC-157
    Outcome
    IncreaseVEGFR2 protein expression
    Study

    humann: not reported in source

    Human vascular endothelial cells
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro study using human vascular endothelial cells further confirmed the increased mRNA and protein expressions of VEGFR2 but not VEGF-A by BPC 157.
  8. 08LabIn vitro (cells)Mechanism

    In human vascular endothelial cells, BPC‑157 did not increase VEGF-A expression.

    In plain wordsIn human blood vessel cells in the lab, BPC‑157 did not raise VEGF-A.

    Peptide
    BPC-157
    Outcome
    No significant changeVEGF-A expression
    Study

    humann: not reported in source

    Human vascular endothelial cells
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro study using human vascular endothelial cells further confirmed the increased mRNA and protein expressions of VEGFR2 but not VEGF-A by BPC 157.
  9. 09LabIn vitro (cells)Mechanism

    In vascular endothelial cells, BPC‑157 promoted VEGFR2 internalization.

    In plain wordsIn blood vessel cells in the lab, BPC‑157 promoted uptake of the VEGFR2 receptor into the cell.

    Peptide
    BPC-157
    Outcome
    IncreaseVEGFR2 internalization
    Study

    n: not reported in source

    Vascular endothelial cells
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, BPC 157 could promote VEGFR2 internalization in vascular endothelial cells which was blocked in the presence of dynasore, an inhibitor of endocytosis.
  10. 10LabIn vitro (cells)Mechanism

    In vascular endothelial cells, BPC‑157 activated the VEGFR2-Akt-eNOS signaling pathway in a time-dependent way.

    In plain wordsIn blood vessel cells in the lab, BPC‑157 switched on the VEGFR2-Akt-eNOS signaling pathway over time.

    Peptide
    BPC-157
    Outcome
    IncreaseVEGFR2-Akt-eNOS pathway activation
    Study

    n: not reported in source

    Vascular endothelial cells
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    BPC 157 time dependently activated the VEGFR2-Akt-eNOS signaling pathway which could also be suppressed by dynasore.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.